IO Biotech, Inc. — Director's Dealing 2023

Aug 21, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2023-08-09

Reporting Person: Kurma Partners (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4345679	Indirect
Common Stock	1852026	Indirect
Common Stock	623428	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants (Right to Buy)	$2.47		Common Stock (4345679)		Indirect
Warrants (Right to Buy)	$2.47		Common Stock (812815)		Indirect
Warrants (Right to Buy)	$2.47		Common Stock (273603)		Indirect

Footnotes

F1: The securities are held by Kurma Growth Opportunities Fund FPCI. Kurma Partners is the management company of Kurma Growth Opportunities Fund FPCI.

F2: The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI.

F3: The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI.

F4: The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.

F5: These warrants expire at 5:00 p.m. Eastern time on the earlier of (i) February 9, 2027, and (ii) one day prior to the closing of an Acquisition (as such term is defined in the Form of Warrant, attached as Exhibit 4.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2023).